Illumina (NASDAQ:ILMN) Director Keith Meister Sells 68,108 Shares

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 68,108 shares of Illumina stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $213.28, for a total transaction of $14,526,074.24. Following the completion of the transaction, the director directly owned 965,802 shares in the company, valued at approximately $205,986,250.56. The trade was a 6.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Illumina Trading Down 1.6%

NASDAQ:ILMN opened at $218.22 on Friday. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $231.81. The firm has a 50 day moving average of $198.42 and a 200 day moving average of $159.03. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $32.95 billion, a price-to-earnings ratio of 40.71, a PEG ratio of 3.14 and a beta of 1.46.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Argus raised its price target for Illumina (ILMN) from $180 to $235 and upgraded the stock to “buy,” implying additional upside from recent levels. The bullish view reflects confidence in Illumina’s earnings outlook and continued demand for genomic sequencing.
• Neutral Sentiment: Broader biotechnology coverage was mixed. 10x Genomics’ strong rally, supported by consumables growth and improved guidance, highlights investor interest in life-sciences tools, although weak instrument demand and valuation concerns remain sector risks. 10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
• Neutral Sentiment: Articles about robotics and AI-focused ETFs may support long-term interest in technology and automation themes, but they do not represent a direct catalyst for Illumina’s business or stock. Are Robots the New Normal? Bet on these ETFs to Invest in the Future
• Negative Sentiment: Zacks Research downgraded ILMN from “strong buy” to “hold.” The change introduces caution after the stock’s substantial advance and suggests that current valuation and expectations may leave less room for execution missteps. Illumina Analyst Downgrade
• Negative Sentiment: PacBio’s reduced 2026 outlook, attributed to weaker instrument demand and slower clinical adoption, is a modest negative read-through for the sequencing market. Although PacBio is a competitor rather than an Illumina subsidiary, the update raises questions about the pace of demand across the industry. PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test

Hedge Funds Weigh In On Illumina

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ILMN. Elyxium Wealth LLC acquired a new stake in Illumina during the 4th quarter worth about $25,000. Fiduciary Financial Advisors acquired a new position in shares of Illumina in the second quarter valued at about $26,000. Keating Financial Advisory Services Inc. acquired a new position in shares of Illumina in the second quarter valued at about $32,000. Quarry LP purchased a new position in shares of Illumina in the third quarter worth about $32,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Illumina in the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

ILMN has been the topic of several recent analyst reports. TD Cowen upped their target price on Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Citigroup boosted their price target on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research note on Monday, August 3rd. Sanford C. Bernstein restated a “market perform” rating and set a $215.00 price objective on shares of Illumina in a report on Friday, July 31st. Royal Bank Of Canada upped their price objective on shares of Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Finally, Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research note on Thursday, May 14th. Nine research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $191.31.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.